Product Description
DEPDC1B Antibody | 8283 | ProSci
Host: Rabbit
Reactivity: Human
Homology: Predicted species reactivity based on immunogen sequence: Mouse: (94%) , Chicken: (88%)
Immunogen: DEPDC1B antibody was raised against a 19 amino acid peptide near the carboxy terminus of human DEPDC1B.
The immunogen is located within the last 50 amino acids of DEPDC1B.
Research Area: Cancer, Cell Cycle
Tested Application: E, WB, IHC-P
Application: DEPDC1B antibody can be used for detection of DEPDC1B by Western blot at 1 - 2 μg/ml. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Specificiy: DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.
Positive Control 1: Cat. No. 1204 - K562 Cell Lysate
Positive Control 2: Cat. No. 10-901 - Human Spleen Tissue Slide
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Predicted: 58 kDa
Observed: 57 kDa
Validation: N/A
Isoform: N/A
Purification: DEPDC1B antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: DEPDC1B antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: DEPDC1B antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: DEP domain-containing 1B, DEP1B, BRCC3, Breast cancer cell 3, XTP1
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1) . Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2, 3) . Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2) .